Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

Cancer

Volumn 116, Issue 6, 2010, Pages 1446-1453

  Overman, Michael J ^a   Kazmi, Syed M ^a   Jhamb, Jagriti ^a   Lin, E ^a   Yao, James C ^a   Abbruzzese, James L ^a   Ho, Linus ^a   Ajani, Jaffer ^a   Phan, Alexandria ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

5 fluorouracil; Cisplatin; Docetaxel; Esophageal cancer; Gastric cancer

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL CANCER; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TAXOIDS;

EID: 77949414964     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24925     Document Type: Article

References (19)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2006/. Based on November 2008 SEER data submission. Accessed May 2009.
2. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
4. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3210-3216.
5. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205-3209.
6. Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol. 2007;25:3188-3190.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-2909.
9. Hainsworth JD, Burris HA 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001;19:3500-3505.
10. Hainsworth JD, Greco FA. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2002;3(suppl 2):S17-S22.
11. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004; 15:1358-1365.
12. Koppert LB, Janssen-Heijnen ML, Louwman MW, et al. Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study. Eur J Gastroenterol Hepatol. 2004;16:681-688.
13. Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673-1679.
14. Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389-2396.
15. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865-867.
16. Park SR, Chun JH, Kim YW, et al. Phase II study of lowdose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 2005;28:433-438.
17. Tebbutt NC, Sourjina T, Strickland A, et al. ATTAX: randomized phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophagogastric cancer. Final result of an AGITG Trial. ASCO Annual Meeting Proceedings pt I. J Clin Oncol. 2007;25(suppl 18S):4528.
18. Ajani JA, Phan A, Ho L, Tetzlaff ED, Baker J, Wei Q. Phase I/ II trial of docetaxel plus oxaliplatin and 5-fluorouracil (DFOX) in patients with untreated, advanced gastric or gastroesophageal cancer [abstract]. J Clin Oncol. 2007;25:4612.
19. Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19: 1882-1887.